- Home
- VTMX vs REVBW Comparison
VTMX vs REVBW Comparison
Compare VTMX & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- REVBW
- Stock Information
- Founded
- VTMX 1998
- REVBW N/A
- Country
- VTMX Mexico
- REVBW United States
- Employees
- VTMX N/A
- REVBW 9
- Industry
- VTMX
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- VTMX
- REVBW Health Care
- Exchange
- VTMX Nasdaq
- REVBW Nasdaq
- Market Cap
- VTMX N/A
- REVBW N/A
- IPO Year
- VTMX 2023
- REVBW 2020
- Fundamental
- Price
- VTMX $24.27
- REVBW N/A
- Analyst Decision
- VTMX Sell
- REVBW
- Analyst Count
- VTMX 2
- REVBW 0
- Target Price
- VTMX $27.50
- REVBW N/A
- AVG Volume (30 Days)
- VTMX 159.0K
- REVBW N/A
- Earning Date
- VTMX 04-23-2025
- REVBW N/A
- Dividend Yield
- VTMX 2.88%
- REVBW N/A
- EPS Growth
- VTMX N/A
- REVBW N/A
- EPS
- VTMX 0.25
- REVBW N/A
- Revenue
- VTMX $252,327,122.00
- REVBW N/A
- Revenue This Year
- VTMX $22.81
- REVBW N/A
- Revenue Next Year
- VTMX $9.13
- REVBW N/A
- P/E Ratio
- VTMX $8.61
- REVBW N/A
- Revenue Growth
- VTMX 17.65
- REVBW N/A
- 52 Week Low
- VTMX $21.30
- REVBW N/A
- 52 Week High
- VTMX $37.92
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- VTMX 55.92
- REVBW N/A
- Support Level
- VTMX $21.30
- REVBW N/A
- Resistance Level
- VTMX $23.49
- REVBW N/A
- Average True Range (ATR)
- VTMX 1.01
- REVBW 0.00
- MACD
- VTMX 0.16
- REVBW 0.00
- Stochastic Oscillator
- VTMX 77.14
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).